BioMarin Pharmaceutical (NASDAQ:BMRN) updated its FY18 earnings guidance on Wednesday. The company provided EPS guidance of $0.57-0.79 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.70. The company issued revenue guidance of $1.47-1.53 billion, compared to the consensus revenue estimate of $1.49 billion.
A number of equities analysts have weighed in on BMRN shares. Sanford C. Bernstein decreased their price target on shares of BioMarin Pharmaceutical from $97.00 to $92.00 and set a market perform rating on the stock in a report on Monday, April 30th. BMO Capital Markets restated an outperform rating and set a $125.00 target price (up previously from $119.00) on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. BidaskClub upgraded shares of BioMarin Pharmaceutical from a sell rating to a hold rating in a report on Tuesday, May 8th. ValuEngine raised shares of BioMarin Pharmaceutical from a sell rating to a hold rating in a research note on Friday, May 11th. Finally, Credit Suisse Group reaffirmed a buy rating and set a $116.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, March 29th. Seven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. BioMarin Pharmaceutical presently has a consensus rating of Buy and a consensus price target of $111.15.
BMRN stock opened at $88.43 on Friday. The company has a current ratio of 2.90, a quick ratio of 2.29 and a debt-to-equity ratio of 0.29. The company has a market cap of $15.82 billion, a PE ratio of -131.99 and a beta of 1.68. BioMarin Pharmaceutical has a 52-week low of $88.57 and a 52-week high of $89.39.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.06). BioMarin Pharmaceutical had a negative return on equity of 3.01% and a negative net margin of 10.48%. The business had revenue of $358.31 million during the quarter, compared to the consensus estimate of $346.24 million. equities research analysts anticipate that BioMarin Pharmaceutical will post -0.12 EPS for the current fiscal year.
In other BioMarin Pharmaceutical news, Director V Bryan Lawlis sold 3,750 shares of the firm’s stock in a transaction dated Tuesday, April 17th. The shares were sold at an average price of $85.00, for a total value of $318,750.00. Following the completion of the sale, the director now owns 18,610 shares in the company, valued at approximately $1,581,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP George Eric Davis sold 2,105 shares of the firm’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $79.04, for a total transaction of $166,379.20. Following the completion of the transaction, the executive vice president now directly owns 90,089 shares in the company, valued at approximately $7,120,634.56. The disclosure for this sale can be found here. Insiders have sold a total of 149,087 shares of company stock valued at $12,679,085 in the last quarter. 1.90% of the stock is currently owned by corporate insiders.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.